Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer

Breast Cancer Research

Volumn 15, Issue 1, 2012, Pages

  Agnihotri, Navneet ^a,b   Kumar, Santosh ^a,c   Mehta, Kapil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PANJAB UNIVERSITY   (India)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBRONECTIN; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; KCC 009; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOSARCOMA; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MEDIATOR; METASTASIS; MULTIPLE CANCER; PHENOTYPE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SCAR FORMATION; BREAST TUMOR; ENZYMOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GTP-BINDING PROTEINS; HUMANS; INFLAMMATION; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84874258198     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3371     Document Type: Review

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Radisky E, Radsky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007, 8:279-287. 10.1007/s11154-007-9037-1, 17447144.
3. Mehta K, Kumar A, Kim HI. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 2010, 80:1921-1929. 10.1016/j.bcp.2010.06.029, 20599779.
4. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156. 10.1038/nrm1014, 12563291.
5. Kiraly R, Demeny M, Fesus L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J 2011, 278:4717-4739. 10.1111/j.1742-4658.2011.08345.x, 21902809.
6. Nurminskaya MV, Belkin AM. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 2012, 294:1-97.
7. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 2007, 10:144-151. 10.1016/j.drup.2007.06.002, 17662645.
8. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004, 10:8068-8076. 10.1158/1078-0432.CCR-04-1107, 15585642.
9. Mangala LS, Fok Y, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470. 10.1038/sj.onc.1210035, 17043648.
10. Oh K, Ko E, Kim HS, Park AK, Moon HG, Noh DY, Lee DS. Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res 2011, 13:R96. 10.1186/bcr3034, 3262209, 21967801.
11. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrugresistant human MCF-7 breast adenocarcinoma cells reveals novel hyper and hypomethylated targets. Mol Cancer Ther 2007, 6:1089-1098. 10.1158/1535-7163.MCT-06-0663, 17363502.
12. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 2008, 29:510-518.
13. Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA 2010, 107:1408-1413. 10.1073/pnas.0907907107, 2824373, 20080707.
14. Wang Y, Ande SR, Mishra S. Phosphorylation of transglutaminase 2 (TG2) at serine-216 plays a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN. BMC Cancer 2012, 12:277. 10.1186/1471-2407-12-277, 3492171, 22759359.
15. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
16. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-887. 10.1016/j.cell.2009.11.007, 19945376.
17. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997. 10.1158/0008-5472.CAN-07-2017, 18281472.
18. Geradts J, de Herreros AG, Su Z, Burchette J, Broadwater G, Bachelder RE. Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. Hum Pathol 2011, 42:1125-1131. 10.1016/j.humpath.2010.11.004, 3315281, 21315410.
19. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5:e13390. 10.1371/journal.pone.0013390, 2953521, 20967228.
20. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 2010, 13:99-108. 10.1016/j.drup.2010.08.001, 20739212.
21. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010, 102:1637-1652. 10.1093/jnci/djq361, 2970576, 20935265.
22. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
24. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005, 23:1169-1177. 10.1200/JCO.2005.03.156, 15718313.
25. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 2011, 6:e20701. 10.1371/journal.pone.0020701, 3110765, 21687668.
26. Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2012, 14:R4. 10.1186/bcr3085, 3496119, 22225906.
27. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012, 31:2521-2534. 10.1038/onc.2011.429, 21963846.
28. Shostak K, Chariot A. NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 2011, 13:214. 10.1186/bcr2886, 3236328, 21867572.
29. Ai L, Skehan RR, Saydi J, Lin T, Brown KD. Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem 2012, 287:18330-18341. 10.1074/jbc.M112.339317, 22493284.
30. Ghanta KS, Pakala SB, Reddy SD, Li DQ, Nair SS, Kumar R. MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. J Biol Chem 2011, 286:7132-7138. 10.1074/jbc.M110.199273, 3044970, 21156794.
31. Kumar S, Mehta K. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical path. PLoS One 2012, 7:e49321. 10.1371/journal.pone.0049321, 3501523, 23185316.
32. Park KS, Kim DS, Jeong KC, Kim SY. Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front Biosci 2009, 14:1945-1951.
33. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 2006, 66:10936-10943. 10.1158/0008-5472.CAN-06-1521, 17108131.
34. Kim SY. Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. Adv Enzymol Relat Areas Mol Biol 2011, 78:161-195.
35. Kim Y, Eom S, Kim K, Lee YS, Choe J, Hahn JH, Lee H, Kim YM, Ha KS, Ro JY, Jeoung D. Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol Immunol 2010, 47:1010-1022. 10.1016/j.molimm.2009.11.017, 20004474.
36. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410. 10.1038/nrc3064, 21606941.
37. Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene 2011, 30:4780-4790. 10.1038/onc.2011.183, 21625219.
38. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003, 103:642-646. 10.1002/ijc.10833, 12494472.
39. Cieply B, Riley P 4, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, Denvir J, Frisch SM. Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res 2012, 72:2440-2453. 10.1158/0008-5472.CAN-11-4038, 22379025.
40. Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, Cerione RA. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin induced apoptosis in human breast cancer cells. J Biol Chem 2004, 279:41461-41467. 10.1074/jbc.M404976200, 15272014.
41. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 2009, 284:17914-17925. 10.1074/jbc.M109.013037, 2709351, 19403524.
42. Wang Y, Ande SR, Mishra S. Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor. Biochem Biophys Res Commun 2012, 417:251-255. 10.1016/j.bbrc.2011.11.094, 22142843.
43. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906. 10.1016/j.cell.2009.10.027, 2788004, 19931152.
44. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5849-5858. 10.1158/0008-5472.CAN-07-6130, 2547344, 18632639.
45. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 2008, 14:2476-2483. 10.1158/1078-0432.CCR-07-4529, 18413840.
46. Badarau E, Collighan RJ, Griffin M. Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids 2013, 44:119-127. 10.1007/s00726-011-1188-4, 22160259.
47. Budillon A, Carbone C, Gennaro ED. Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids 2013, 44:63-72. 10.1007/s00726-011-1167-9, 3535412, 22130737.
48. Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 2007, 5:e327. 10.1371/journal.pbio.0050327, 2140088, 18092889.
49. Yuan L, Holmes TC, Watts RE, Khosla C, Broekelmann TJ, Mecham R, Zheng H, Izaguirre EW, Rich KM. Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol 2011, 103:207-219. 10.1007/s11060-010-0379-2, 20824305.